BMY Bristol-Myers Squibb Co. Forward P/S Multiple

Bristol-Myers Squibb - graphic logo of issuer BMY

The defensive status of Bristol-Myers Squibb (BMY) ensures stable demand for cardiology and oncology drugs regardless of macroeconomic conditions. The issuer's forward P/S visualizes this resilience, while the 1.70 level indicates the state of the valuation parameter relative to future revenues. The holding company outsources a portion of its research and logistics to external contractors. Currently, Bristol-Myers Squibb (BMY) is updating its portfolio through the acquisition of biotech assets to overcome the period of patent expiration.

BMY bms.com: Forward Price to Sales in the range 07/04/2022 - 11/17/2026

Analytical breakdowns for Bristol-Myers Squibb

General company analysis:BMY (bms.com)
Original product of bms.com

Scaling robotic synthesis and packaging of biologics at Bristol-Myers Squibb (BMY) should optimize costs and increase revenue. The forward P/S ratio compares current market capitalization with expected sales volume, allowing for the determination of the fair value of a future business acquisition. Analyzing the extremes in the forward P/S dynamics of Bristol-Myers Squibb (BMY) helps investors assess the validity of the control premium over assets relative to industry standards.